Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Revvity Inc (RVTY) Price & Performance

iShares MSCI Taiwan ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Revvity Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.06 (market cap $12.74B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Revvity Inc for 12 Days on average.

EWTRVTY
Market Cap
$12.74B$16.98B
Volume
8,470,9201,456,900
Sector
Broad Market / FactorHealth
52-Week High
$118.00$157.36
52-Week Low
$60.03$82.26
Typical Hold Time
52 Days12 Days
Enterprise Value
—$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT trades at $114.01, down 1.92% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of its portfolio. Recent news highlights Taiwan's strategic importance in AI chip manufacturing and ongoing US-Taiwan economic cooperation, with Taiwanese companies planning $20 billion in US investments driven by AI demand (Reuters, 2026-09-02).

The outlook remains positive given Taiwan's central role in AI semiconductor supply chains, though geopolitical tensions with China present significant risks. Analyst sentiment is generally bullish with institutional investors increasing positions, including Bank of America's 22.4% stake increase in Q2 2026. Key support levels at $110-$112 provide downside protection while resistance sits at $115-$117.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWT
93% Buy7% Sell
Avg holding period · 52 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →